Edit
Fluidx Medical Technology, Inc.
https://www.fluidxmedical.com/Last activity: 02.04.2026
Active
The GPX and IMPASS Embolic Device platforms are under development and do not have marketing clearance or approval in any market at this time.
Location: United States, Utah, Salt Lake City
Employees: 11-50
Investors 1
| Date | Name | Website |
| - | MedMountai... | mmv.vc |
Mentions in press and media 6
| Date | Title | Description |
| 02.04.2026 | Fluidx Medical Announces First Patient Treated with Novel Embolic Gel | The ULTRA Embolic Device is designed for use in embolization of tumors and peripheral vascular hemorrhage. Gel embolic device designed to simplify the embolization procedure and reduce risks to the patient. We could see the material very we... |
| 10.02.2026 | Fluidx IDE Trial Results Accepted for Late-Breaking Presentation at the SIR Annual Meeting | First podium presentation of IDE Clinical Trial Data of Novel Embolic Device to Treat Cancer The SIR clinical community will be key users of our next-gen gel embolic materials and we are excited that the first podium presentation will be at... |
| 07.01.2026 | IDE Pivotal Trial for Novel Liquid Embolic Device Completes Enrollment | Enrollment completed across 18 clinical sites with 40+ investigators in the US, Canada, and New Zealand If the GPX trial can confirm the positive results of the earlier study published in JVIR, it could help establish GPX as an important ne... |
| 27.11.2024 | Fluidx Medical Announces First Tumor Patient Treated in Prospective, Multinational Trial | The GPX Embolic Device is designed to occlude tumors and other distal applications Embolic device designed for improved preparation, delivery, and deep vessel filling for treating tumors and other interventional oncology uses. We are please... |
| 21.05.2024 | New Embolic Device for Tumor Treatment and Other Oncology Uses Given Nod by FDA to Start Pivotal Clinical Trial | Post-embolization angiogram of the GPX Embolic Device filling a pelvic tumor (as featured on the cover of Journal of Vascular and Interventional Radiology, February 2024) Investigators look forward to evaluating the new device designed for ... |
| 23.04.2021 | Christopher Phillips Named Chair of the BioUtah Regulatory, Compliance and Quality Committee | BioUtah today announced that Christopher Phillips, director of regulatory affairs and clinical affairs at Fluidx Medical Technology, has been appointed chair of BioUtah’s Regulatory, Compliance and Quality Committee. Phillips takes the rein... |